Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Branded Pharmaceutical Products R&D, Inc.
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willing to provide informed consent.
Male or female, 18 years of age or older, with a diagnosis of MS.
You may not be if
Has been on oral or parenteral corticosteroid therapy within the two weeks prior to the Baseline Visit.
Has been treated with immunoglobulins (IgG) or plasmapheresis within the last six months.
Has any condition which the investigator or nurse feels may interfere with participation in the study or with assessments for the full duration of the study.
Previously participated in this study.
Has received an experimental drug in the last thirty (30) days.
